Novo Nordisk A/S Shares Data from Kidney Outcomes Study
Novo Nordisk A/S (NYSE: NGOs) has shared knowledge from its kidney outcomes research, FLOW, showcasing promising outcomes for the remedy of sort 2 diabetes. The research examined once-weekly injectable Ozempic on 3,533 sufferers over a 3.4-year interval.
In March, the corporate launched headline knowledge revealing a 24% discount in kidney illness development and cardiovascular and kidney deaths. This knowledge was introduced on the European Renal Association Congress by Professor Vlado Perkovic.
Detailed findings from the FLOW research confirmed important enchancment in secondary endpoints with semaglutide. The development of glomerular filtration price (eGFR) was slower, main cardiovascular occasions had been diminished by 18%, and the chance of dying from all causes decreased by 20%.
According to Professor Perkovic, using semaglutide in people with sort 2 diabetes and power kidney illness can scale back the chance of main kidney results and cardiovascular occasions. These outcomes have the potential to reshape remedy methods and supply new methods to guard the kidneys and cardiovascular system.
Despite the constructive findings, shares of NVO traded down 0.67% at $134.66 in late buying and selling on Friday. For extra updates on this subject, keep tuned to Calling Italy and comply with us on our social channels.
In conclusion, the FLOW research by Novo Nordisk A/S demonstrates a big step in direction of enhancing remedy outcomes for people with sort 2 diabetes and power kidney illness. The potential advantages of semaglutide recommend a promising future for sufferers at excessive danger of diabetes-related problems.